Literature DB >> 33665647

Cathepsin D: A Candidate Link between Amyloid β-protein and Tauopathy in Alzheimer Disease.

Caitlin N Suire1, Malcolm A Leissring1.   

Abstract

Alzheimer disease (AD) is a debilitating neurodegenerative disorder characterized by extracellular deposition of the amyloid β-protein (Aβ) and intraneuronal accumulation of the microtubule-associated protein, tau. Despite a wealth of experimental and genetic evidence implicating both Aβ and tau in the pathogenesis of AD, the precise molecular links between these two pathological hallmarks have remained surprisingly elusive. Here, we review emerging evidence for a critical nexus among Aβ, tau, and the lysosomal protease cathepsin D (CatD) that we hypothesize may play a pivotal role in the etiology of AD. CatD degrades both Aβ and tau in vitro, but the in vivo relevance of this lysosomal protease to these principally extracellular and cytosolic proteins, respectively, had remained undefined for many decades. Recently, however, our group found that genetic deletion of CatD in mice results in dramatic accumulation of Aβ in lysosomes, revealing that Aβ is normally trafficked to lysosomes in substantial quantities. Moreover, emerging evidence suggests that tau is also trafficked to the lysosome via chaperone-mediated autophagy and other trafficking pathways. Thus, Aβ, tau and CatD are colocalized in the lysosome, an organelle that shows dysfunction early in AD pathogenesis, where they can potentially interact. Notably, we discovered that Aβ42-the Aβ species most strongly linked to AD pathogenesis-is a highly potent, low-nanomolar, competitive inhibitor of CatD. Taking these observations together, we hypothesize that Aβ42 may trigger tauopathy by competitive inhibition of CatD-mediated degradation of tau-pathogenic forms of tau, in particular. Herein, we review the evidence supporting this hypothesis and explore the implications for the molecular pathogenesis of AD. Future research into these novel mechanistic links among Aβ, tau and CatD promises to expand our understanding of the etiology of AD and could potentially lead to novel therapeutic approaches for combatting this devastating disease of brain and mind.

Entities:  

Keywords:  Alzheimer disease; Amyloid β-protein; Cathepsin D; Lysosome; Tau

Year:  2021        PMID: 33665647      PMCID: PMC7929084     

Source DB:  PubMed          Journal:  J Exp Neurol        ISSN: 2692-2819


  45 in total

1.  Cytosolic proteolysis of tau by cathepsin D in hippocampus following suppression of cathepsins B and L.

Authors:  E Bednarski; G Lynch
Journal:  J Neurochem       Date:  1996-11       Impact factor: 5.372

2.  Secretion of Tau via an Unconventional Non-vesicular Mechanism.

Authors:  Maria Merezhko; Cecilia A Brunello; Xu Yan; Helena Vihinen; Eija Jokitalo; Riikka-Liisa Uronen; Henri J Huttunen
Journal:  Cell Rep       Date:  2018-11-20       Impact factor: 9.423

3.  Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease.

Authors:  D Scheuner; C Eckman; M Jensen; X Song; M Citron; N Suzuki; T D Bird; J Hardy; M Hutton; W Kukull; E Larson; E Levy-Lahad; M Viitanen; E Peskind; P Poorkaj; G Schellenberg; R Tanzi; W Wasco; L Lannfelt; D Selkoe; S Younkin
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

4.  The tau protein in human cerebrospinal fluid in Alzheimer's disease consists of proteolytically derived fragments.

Authors:  G V Johnson; P Seubert; T M Cox; R Motter; J P Brown; D Galasko
Journal:  J Neurochem       Date:  1997-01       Impact factor: 5.372

Review 5.  The secretases: enzymes with therapeutic potential in Alzheimer disease.

Authors:  Bart De Strooper; Robert Vassar; Todd Golde
Journal:  Nat Rev Neurol       Date:  2010-02       Impact factor: 42.937

6.  2020 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2020-03-10       Impact factor: 21.566

7.  Differential regulation of amyloid-β endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms.

Authors:  Jie Li; Takahisa Kanekiyo; Mitsuru Shinohara; Yunwu Zhang; Mary Jo LaDu; Huaxi Xu; Guojun Bu
Journal:  J Biol Chem       Date:  2012-11-06       Impact factor: 5.157

Review 8.  Aging and Alzheimer's disease pathology.

Authors:  Renpei Sengoku
Journal:  Neuropathology       Date:  2019-12-21       Impact factor: 1.906

Review 9.  Tau filaments in neurodegenerative diseases.

Authors:  Michel Goedert
Journal:  FEBS Lett       Date:  2018-07-06       Impact factor: 4.124

10.  Extracellular Monomeric and Aggregated Tau Efficiently Enter Human Neurons through Overlapping but Distinct Pathways.

Authors:  Lewis D Evans; Thomas Wassmer; Graham Fraser; James Smith; Michael Perkinton; Andrew Billinton; Frederick J Livesey
Journal:  Cell Rep       Date:  2018-03-27       Impact factor: 9.423

View more
  4 in total

1.  Exercise Rehabilitation and/or Astragaloside Attenuate Amyloid-beta Pathology by Reversing BDNF/TrkB Signaling Deficits and Mitochondrial Dysfunction.

Authors:  Yu-Lin Wang; Chung-Ching Chio; Shu-Chun Kuo; Chao-Hung Yeh; Jui-Ti Ma; Wen-Pin Liu; Mao-Tsun Lin; Kao-Chang Lin; Ching-Ping Chang
Journal:  Mol Neurobiol       Date:  2022-03-09       Impact factor: 5.590

Review 2.  Cathepsin D-Managing the Delicate Balance.

Authors:  Olja Mijanovic; Anastasiia I Petushkova; Ana Brankovic; Boris Turk; Anna B Solovieva; Angelina I Nikitkina; Sergey Bolevich; Peter S Timashev; Alessandro Parodi; Andrey A Zamyatnin
Journal:  Pharmaceutics       Date:  2021-06-05       Impact factor: 6.321

3.  Insulin-Degrading Enzyme: Paradoxes and Possibilities.

Authors:  Malcolm A Leissring
Journal:  Cells       Date:  2021-09-16       Impact factor: 6.600

Review 4.  Proteolytic α-Synuclein Cleavage in Health and Disease.

Authors:  Alexandra Bluhm; Sarah Schrempel; Stephan von Hörsten; Anja Schulze; Steffen Roßner
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.